PRINCETON, N.J., 2 December 2022 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced Pablo Pergola, MD, Ph.D. Renal Associates PA, San Antonio, TX, presented an overview of Ocedurenone (KBP-5074) in stage 4 CKD HTN patients at the American Society of Nephrology (ASN) Kidney Week Conference November 4, 2022. The title of the oral presentations was “Nonsteroidal Mineralocorticoid Receptor Blocker (KBP-5074) for Hypertension in Stage 4 CKD” with moderators Drs. George Bakris and Karen Griffin.
Uncontrolled and resistant hypertension is a major contributor to the excess morbidity and mortality in patients with advanced kidney disease. Dr Pablo Pergola presented the BLOCK CKD 2b trial data for Ocedurenone efficacy and safety. He provided a review of Ocedurenone properties that lead to better BP reduction and minimal risk of hyperkalemia in patients with resistant hypertension having advanced CKD. The ongoing Phase 3 study: CLARION CKD – Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension with Moderate to Severe CKD: Clinicaltrials.gov NCT04968184 was presented.
In conclusion, Dr Pergola stated that “Ocedurenone demonstrates potential as a new treatment option for high-risk patients with cardiovascular disease and chronic kidney disease progression that suffer from uncontrolled or resistant hypertension”.
Dr George Bakris, MD, Director of the American Heart Association’s Comprehensive Hypertension Center at the University of Chicago Medical Center and session moderator, was asked about the renal mechanism for BP lowering but not causing significant hyperkalemia. “This is not like Spironolactone. It is a non-steroidal MRA and is clearly different. It has different binding properties to the mineralocorticoid receptor with cofactors and gene activation, as well as other physiologic factors that lead to less hyperkalemia.”
“The presentation and overview of the novel nonsteroidal MRA Ocedurenone by Dr Pablo Pergola adds further confidence and excitement on the successful development of a drug that will help solve the unmet medical need of patients suffering uncontrolled or resistant hypertension with advanced chronic kidney disease” said Dr James McCabe Deputy Chief Medical Officer.
About ASN Kidney Week
The world's premier nephrology meeting, Kidney Week provides participants exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
About KBP Biosciences
KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs. KBP Biosciences’ pipeline includes 4 novel drug candidates, 2 currently in clinical development covering multiple indications. CLARION-CKD, the Phase 3 clinical trial of Ocedurenone (KBP-5074), with the first indication of advanced CKD and uncontrolled hypertension, is being conducted globally.
About Ocedurenone(KBP-5074)
Ocedurenone (KBP-5074) is a non-steroidal MRA discovered and developed by KBP Biosciences. Ocedurenone (KBP-5074) selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects. At present, the Phase III clinical trial of the first indications of Ocedurenone (KBP-5074), advanced CKD and uncontrolled hypertension, is being conducted globally. Other indications of Ocedurenone are planned, including CV, CKD Progression, etc. Ocedurenone (KBP-5074) has been investigated in nine clinical studies including the BLOCK-CKD Phase 2b study. Ocedurenone(KBP-5074) is expected to provide a new treatment option addressing the unmet medical needs of patients with advanced CKD and uncontrolled hypertension.
About Advanced Chronic Kidney Disease (CKD) and Uncontrolled Hypertension
Current estimates of the prevalence of CKD indicate that there are 138 million adults with CKD in China alone. Available MRAs can provide additional blood pressure control in some of these patients, but usually will increase the risk of hyperkalemia. Many patients with stage 3b/4 CKD are at their maximum tolerated dose of anti-hypertensive medications and still have uncontrolled or resistant hypertension. Therefore, there is a huge unmet medical need in these patients.
For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/
Contacts:
Investor Relations:
ir@kbpbiosciences.com
Public Relations:
pr@kbpbiosciences.com